Clinical Trial Update: Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 trial assessing infectivity, safety, and immunogenicity of recombinant live-attenuated RSV vaccines in RSV-seronegative infants aged 6–24 months; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV 276
• RSV ΔNS2/Δ1313/I1314L

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2021-01-08